©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Dec 15, 2015; 7(12): 445-454
Published online Dec 15, 2015. doi: 10.4251/wjgo.v7.i12.445
Published online Dec 15, 2015. doi: 10.4251/wjgo.v7.i12.445
Outcome following incomplete surgical cytoreduction combined with intraperitoneal chemotherapy for colorectal peritoneal metastases
Roisin Mary Heaney, Conor Shields, Jurgen Mulsow, Peritoneal Malignancy Institute, Mater Misericordiae University Hospital, Dublin 7, Ireland
Author contributions: Heaney RM performed the literature search, compiled the data and drafted and revised the article; Shields C and Mulsow J drafted and revised the article.
Conflict-of-interest statement: The authors declare no conflict of interest.
Correspondence to: Roisin Mary Heaney, MB, BCh, MRCS, Peritoneal Malignancy Institute, Mater Misericordiae University Hospital, Eccles Street, Dublin 7, Ireland. heaneyr@tcd.ie
Telephone: +353-18545091
Received: April 29, 2015
Peer-review started: May 7, 2015
First decision: June 6, 2015
Revised: June 20, 2015
Accepted: September 30, 2015
Article in press: October 9, 2015
Published online: December 15, 2015
Processing time: 229 Days and 20 Hours
Peer-review started: May 7, 2015
First decision: June 6, 2015
Revised: June 20, 2015
Accepted: September 30, 2015
Article in press: October 9, 2015
Published online: December 15, 2015
Processing time: 229 Days and 20 Hours
Core Tip
Core tip: Cytoreductive surgery combined with intraperitoneal chemotherapy for colorectal peritoneal metastases improves survival in appropriately selected patients following complete cytoreduction. The merits of an incomplete cytoreduction, with or without intraperitoneal chemotherapy, are unclear. The available evidence is heterogenous and of poor quality. The current review has not shown a benefit to surgery in the setting of unresectable disease. Certain patients, particularly those with ascites may however gain from a quality of life point of view.